Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma

Figure 3 Analysis of relationship between protein tyrosine phosphatase non-receptor 2 expression and the immune microenvironment in hepatocellular carcinoma. A: Enrichment of differentially expressed genes between the high and low protein tyrosine phosphatase non-receptor 2 (PTPN2) expression groups in the hallmark pathways of hepatocellular carcinoma (HCC). The results showed that genes upregulated in PTPN2-high vs PTPN2-low samples in HCC mainly regulate immune activation and inflammatory response through the Wnt signaling pathway, Hedgehog signaling pathway, interleukin (IL)6-Janus kinase-signal transducer and activator of transcription (STAT)3 signaling pathway, IL2-STAT5 signaling pathway, KRAS signaling pathway, and inflammatory response; B: Differential functional analysis of immune cells in the high and low PTPN2 expression groups of patients with HCC. Blue represents high expression samples, and red represents low expression samples; C: Differential analysis of interstitial signaling pathways in the high and low PTPN2 expression groups of patients with HCC and assessment of immune cell scores. Blue represents high expression samples, and red represents low expression samples; D and E: Immunotherapeutic effect in the high and low PTPN2 expression groups calculated with the ESTIMATE algorithm; ^aP < 0.05; ^bP < 0.01; ^cP < 0.001; ns: P > 0.05. PTPN2: Protein tyrosine phosphatase non-receptor 2.